| Identification | Back Directory | [Name]
L-erythro-Hexonamide, 2,6-anhydro-5-[[[(3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-[3H]indol]-5'-yl]carbonyl]amino]-3,4,5-trideoxy-, 4-methylbenzenesulfonate (1:1) | [CAS]
1398569-75-9 | [Synonyms]
Milademetan free base
L-erythro-Hexonamide, 2,6-anhydro-5-[[[(3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-[3H]indol]-5'-yl]carbonyl]amino]-3,4,5-trideoxy-, 4-methylbenzenesulfonate (1:1) | [Molecular Formula]
C37H42Cl2FN5O7S | [MOL File]
1398569-75-9.mol | [Molecular Weight]
790.73 |
| Hazard Information | Back Directory | [Uses]
Milademetan tosylate is the tosylate salt form of Milademetan (HY-101266). Milademetan tosylate is an orally active inhibitor for MDM2. Milademetan tosylate arrests the cell cycle at G1 pahse, induces the apoptosis Milademetan tosylate restores the p53 activity by targeting the p53-MDM2 interaction, and exhibits anticancer activity against Merkel cell carcinoma (MCC)[1]. | [References]
[1] Ananthapadmanabhan V, et al., Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. JCI Insight. 2022 Jul 8;7(13):e160513. DOI:10.1172/jci.insight.160513 |
|
|